Background: Wounds affect approximately 15 out of every 1000 individuals, representing a significant healthcare challenge. The preclinical evaluation of novel wound treatments is important for advancing therapies that promote effective skin regeneration and improve healing outcomes. Methods: In this study, we integrated existing knowledge from the literature on murine wound healing models, histological features of the skin, and clinical scores described in humans to propose two complementary assessment tools: the HEALS-A histological score (healing, epithelialization, angiogenesis, leukocytes, scar tissue, appendages) and the GRADES clinical score (granulation tissue, redness/edema, appearance of wound, devitalized tissue). Results: These scales combine real-time clinical observation with detailed histological analysis, providing a practical and comprehensive approach to assessing wound healing. Unlike existing wound assessing approaches, HEALS-A does not require specialized software and considers regenerated tissue structures, ensuring a broader and more-detailed evaluation. Conclusions: The assessment of wound closure over time, combined with clinical evaluation and histological analysis of skin, provides a comprehensive approach to determining the true impact of new treatments on skin regeneration and the recovery of its functions in wounds.

Background: COVID-19 is an infectious disease caused by SARS-CoV-2. It is unclear whether influenza vaccination reduces the severity of disease symptoms. Previous studies have suggested a beneficial effect of influenza vaccination on the severity of COVID-19. The aim of this study was to evaluate the possible protective effect of the influenza vaccine on the occurrence of SARS-CoV-2 infection symptoms and prognosis in patients hospitalized with COVID-19. Methods: This was a retrospective cohort study of patients who tested positive for SARS-CoV-2, identified by quantitative real-time polymerase chain reaction. Chi-square tests, Kaplan–Meier analysis, and multivariate analysis were performed to assess the association between influenza vaccination and the presence of symptoms in hospitalized patients with COVID-19 and their outcome. Results: In this study, 1712 patients received positive laboratory tests for SARS-CoV-2; influenza vaccination was a protective factor against the presence of characteristic COVID-19 symptoms such as polypnea, anosmia, dysgeusia, and fever (p < 0.001). Influenza-vaccinated patients had fewer days of hospitalization (p = 0.029). Conclusions: The findings of this study support that influenza vaccination is associated with a decrease in the number of symptoms in patients hospitalized due to COVID-19, with fewer days of hospitalization, but not with the outcome of disease.